The Muscarinic Cholinergic System's Role in Schizophrenia: Pathophysiology and Emerging Treatments
Login to your existing HMP Education account if you have one or create a free account to claim your credit. This session was previously presented at Psych Congress 2022. If you claimed credit for this session at Psych Congress 2022, you are not eligible to claim credit for this session again.
Craig Chepke, MD, FAPA
Medical Director. Excel Psychiatric Associates
Huntersville, North Carolina
Jonathan Meyer, MD
Clinical Professor of Psychiatry
University of California, San Diego
Rakesh Jain, MD, MPH
Clinical Professor, Department of Psychiatry
Texas Tech University School of Medicine - Permian Basin, Midland, Texas
Private Practice, Austin, Texas
Provided by HMP Education, an HMP Global Company.
For questions regarding this educational activity, please call 609-371-1137 or email firstname.lastname@example.org.
This activity is intended for psychiatrists, primary care physicians, psychologists, nurse practitioners, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.
After participating in this activity, learners should be better able to:
- Assess barriers to optimal schizophrenia treatment, and outline strategies to overcome these barriers
- Evaluate the pharmacology, mechanisms of action, safety/efficacy data, and administration considerations associated with novel antipsychotic formulations targeting the muscarinic cholinergic system
- Describe how different MOAs can potentially be synergistic and when it may be beneficial to combine two MOAs to improve efficacy
- Implement strategies for patient-centered communication, including shared decision-making and motivational interviewing, to facilitate treatment selection and acceptance.
To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: November 30, 2022
Expiration Date: November 30, 2023
Estimated Time to Complete: 75 minutes
There is no fee associated with this activity.
In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
HMP Education designates this internet enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education internet enduring activity awards 1.25 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hour.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.25 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.25 general continuing education credits.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither HMP Education nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Education or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- Any investigational, off-label, or non-FDA approved content or discussion
HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
The faculty has reported the following:
Dr. Chepke: Advisory Board—Abbvie, Acadia, Alkermes, Corium, Eisai, Idorsia, Intracellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Takeda, Teva; Advisory Board (Spouse)—Otsuka; Consultant—AbbVie, Alkermes, Corium, Eisai, Intracellular, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Takeda, Teva; Grant Research/Support—Acadia, Axsome, Biohaven, Harmony, Neurocrine, Teva; Speaker’s Bureau—AbbVie, Acadia, Alkermes, Eisai, Intracellular, Ironshore, Janssen, Jazz, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sunovion, Takeda, Teva.
Dr. Meyer: Advisory Board—Alkermes, Intra-Cellular Therapies, Inc., Karuna, Neurocrine, Otsuka America, Inc., Sunovion, Teva. Speakers Bureau— Alkermes, Intra-Cellular Therapies, Inc., Neurocrine, Noven, Sunovion, Teva.
Dr. Jain: Advisory Board—Adamas, Alkermes, Corium, Eisai, Indivior, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva, Tris Pharmaceuticals; Advisory Board (spouse)—Otsuka; Consultant—AbbVie (Allergan), Acadia, Adamas, Alfasigma USA, Inc., Axsome, Corium, Cingulate Therapeutics, Eisai, Evidera, Impel NeuroPharma, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva; Consultant (spouse)—Lilly, Otsuka, Pamlab, Sunovion; Grant/Research Support— AbbVie (Allergan), Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau—AbbVie (Allergan), Alkermes, Axsome, Corium, Eisai, Indivior, Intracellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals; Speakers Bureau (Spouse)—Lilly.
Douglas Noordsy, MD
Clinical Professor Director of Lifestyle Psychiatry
Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine
Palo Alto, California
William C. Torrey, MD
Professor and Vice Chair for Clinical Services
Dartmouth’s Geisel School of Medicine, Dartmouth-Hitchcock
Lebanon, New Hampshire
Dr. Noordsy and Dr. Torrey have disclosed no relevant financial relationship with any ineligible company (commercial interest).
Susie Seaman, NP, MSN, CWOCN (nurse planner)
Wound Clinics, Family Health Centers of San Diego
San Diego, California
Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).
HMP Education planners and staff include Meaghan Benci, Samantha Conforti, Gina Rescinito, Randy Robbin, and Andrea Zimmerman.
No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2022 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at email@example.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint.
The following company has provided an educational grant in support of this activity: Karuna Therapeutics